NCT04338685View on ClinicalTrials.gov

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions
Carcinoma, HepatocellularBiliary Tract CancerSecondary Liver CancerLiver Metastases
Interventions
DRUG

RO7119929

RO7119929 will be administered orally as a capsule

DRUG

Tocilizumab

"Tocilizumab will be administered in case of severe steroid-refractory cytokine release syndrome.~Tocilizumab will be administered as concentrate for solution for IV infusion at a dose: for participants \> 30 kg: 8 mg/kg, for participants \< 30 kg: 12mg/kg IV"

Trial Locations (10)

2100

Rigshospitalet; Onkologisk Klinik, København Ø

10041

National Taiwan Uni Hospital, Taipei

11490

Tri-Service General Hospital, Taipei

28027

Clinica Universidad de Navarra Madrid; Servicio de Oncología, Madrid

31620

Clínica Universidad de Navarra, Pamplona

91010

City of Hope Cancer Center, Duarte

Unknown

Queen Mary Hospital; Dept of Medicine, Hong Kong

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

08035

Hospital Universitari Vall d'Hebron; Oncology, Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT04338685 - A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Biotech Hunter | Biotech Hunter